Drugs / Methyl Prednisolonate
last change Jan 2022 re-read 2 minutes ago

Methyl Prednisolonate

Small molecule

Developed for
hypersensitivity pneumonitis · bursitis
Investigated by
Al-Azhar University

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04402177 Jul 2020 → May 2021 hypersensitivity pneumonitis Al-Azhar University Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT04467450 Comparator Jun → Nov 2020 bursitis Benha University Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT05103397 Comparator Oct 2021 → Jan 2022 Ain Shams University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Methyl Prednisolonate ClinicalTrials.gov intervention name — accepted as the source's own label NCT04402177
2

NCT05103397

NCT04467450

Modality Small molecule “steroid group” NCT04467450
Route Other “ultrasound guided injection of Methyl Prednisolonate in the inflamed subacromial subdeltoid bursa” NCT04467450